Rakovina Therapeutics (TSXV: RKV) has received patents as of this morning. Granted by both the European and Canadian patent offices, the patents are for “Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase”.
The patents that were granted to the company are related to the firms kt-2000 series of drug candidates. The patents cover both the composition of matter as well as the uses of the drug candidates. The k2-2000 series is being studied by the company as a novel series of DNA-damage response inhibitors, which is being targeted as a potential cancer therapy.
With the granting of the patents, the company is to have patent claims in both Canada and the EU until 2032. The granting is expected to support the firms commitment to optimizing the drug candidates for progression towards human clinical trials. The company is currently focused on developing new cancer treatments based on these novel DNA-damage response technologies.
Rakovina Therapeutics last traded at $0.22 on the TSX Venture.
Information for this briefing was found via Sedar and Rakovina Therapeutics. The author has no affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
